Oceaneering International, Inc. (NYSE:OII) announced that T. Jay Collins will retire from his position as President and Chief Executive Officer (NYSE:CEO) immediately following the 2011 Annual Meeting of Shareholders, which is scheduled to be held on May 6, 2011. M. Kevin McEvoy, Oceaneering's Executive Vice President and Chief Operating Officer, has been designated to succeed Mr. Collins as President and CEO. Mr. McEvoy has been with Oceaneering for 32 years, serving since late February 2010 in his current position. He started his offshore career as an officer in the U.S. Navy working in the areas of diving, salvage, and submarine rescue.
Oceaneering International, Inc., together with its subsidiaries, provides engineered products and services primarily to the offshore oil and gas industry with a focus on deepwater applications.
Cancer of the breast is a form of cancer in which cells in the breast split and also grow without usual control. About 85 % of breast cancers begin in the particular mammary ducts, though about 15 per cent happen in the lobules. Tumors within the breasts tend to grow slowly. As soon as a mass is actually big enough in order to come to feel, it may are already thriving for as long as a decade. However, many growths may be severe, and therefore increase far more rapidly.
Parkinson's disease (PD) is associated with a team of disorders called motor system disorders, which are the result of the losing of dopamine-producing brain cells. Some fundamental symptoms of PD are generally tremor, or moving in hands, arms, legs, jaw, and face; hardness, or maybe tightness of the limbs and trunk; bradykinesia, or slowness of movement; and postural lack of stability, or reduced balance as well as co-ordination. Since these symptoms become more evident, patients may have challenges walking, talking, or performing many other very simple tasks.
Power3 Medical Products, Inc. (OTCBB:PWRM.OB), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's, to name a few.
Read more at: http://crwepicks.com/?p=14084